RA-18C3

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RA-18C3, covering 2025-03-30 to 2025-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis [Phase 2]